XML 55 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stockholders Equity and StockBased Compensation (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 04, 2024
May 03, 2023
Aug. 19, 2024
Mar. 29, 2024
Feb. 27, 2024
Nov. 20, 2023
May 28, 2019
Dec. 31, 2024
Dec. 31, 2023
Outstanding restricted stock awards               781,864 557,688
Unrecognized compensation cost related to option awards               $ 3,900,000  
Proceeds from stock option exercise               $ 41,921 $ 0
Stock options vested               445,275 498,177
Common stock, shares, outstanding               18,783,912 13,698,274
Shares of common stock issued               18,783,912 13,698,274
ATM Agreement amendment, description             Under this amended agreement, the Company pays Stifel a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the agreement. The offering of common stock pursuant to this agreement can be terminated with 10 days written notice by either party    
Consulting expense               $ 13,059,497 $ 9,072,638
Stock-based compensation expense               $ 2,038,231 $ 1,257,717
Weighted average grant date fair value               $ 2.91 $ 4.58
Outstanding shares of common stock and ommon stock equivalents               19,248,852 14,209,061
Stock options outstanding               464,940 510,787
Description related to ATM offerings       The Company filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC) on March 29, 2024, registering the sale of up to $75.0 million of the Company’s securities that was declared effective on April 19, 2024. On May 10, 2024, the Company filed a prospectus supplement, which was further supplemented on July 19, 2024 and August 9, 2024 (collectively, the “First Prospectus Supplement”), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $12.6 million from time to time through the ATM. The Company exhausted all sales under the First Prospectus Supplement          
Weighted-average period               2 years 6 months 2 years 1 month 6 days
Available for sale Securities [Member]                  
Proceeds from sale of common stock, shares               4,547,207 1,492,148
Net proceeds from stock issuance under ATM               $ 21,400,000 $ 6,400,000
Stock issuence cost               1,100,000 $ 400,000
Prepaid Expenses And Other Current Assets [Member]                  
Unrecognized compensation cost               $ 114,000  
Expected remaining service period               7 months 6 days  
Common Share Issuances [Member]                  
Shares of common stock issued               18,201 13,325
Stock-based compensation expense               $ 15,000  
Weighted average share price               $ 3.30  
Weighted average grant date fair value               $ 3.30 $ 4.50
Board of Directors Chairman [Member]                  
Common shares issuances equity grant value $ 500,000   $ 180,000     $ 240,000      
Common shares equity grant price per shares $ 5.82         $ 3.97      
Number of shares granted 85,915   71,713     60,456      
Compensation cost recognized     $ 180,000            
Consulting expense               $ 66,000  
Common stock, valued grant date price per share     $ 2.51            
Two Consultants [Member]                  
Shares, Issued               71,330 35,482
Exercise price lower range limit               $ 1.19 $ 1.77
Fair value of the Company's common stock per share               $ 4.73 $ 3.21
Unrecognized compensation cost related to option awards               $ 41,600 $ 41,600
Unrecognized compensation cost related to option awards vesting period               2 years 21 days  
Total fair value               $ 85,000 $ 42,800
Restricted Stock Units R S A [Member] | Board of Directors Chairman [Member]                  
Equity grant approved by board of directors   $ 120,000              
Shares of common stock issued   35,088              
Common shares equity grant price per shares   $ 3.42              
Options [Member]                  
Proceeds from stock option exercise               $ 42,000  
Proceeds from Stock options, shares               10,974  
RSA Summary 2024 and 2023 [Member]                  
Outstanding restricted stock awards               781,864 557,688
Compensation expense               $ 1,400,000 $ 1,200,000
Weighted average grant date fair value               $ 5.82 $ 3.91
2023 Transactions [Member]                  
Equity grant approved by board of directors           $ 1,100,000      
Shares of common stock issued           266,011      
Common shares equity grant price per shares           $ 3.97      
Description about share compensation   35,088 shares were included in the total outstanding common shares at December 31, 2023 and compensation expense will be recognized straight line over the three-year vesting period             a total of 159,727 RSAs vested. These RSAs vest annually with a three-year straight line vesting period. The Company withheld 60,600 shares to make payments for withholding taxes of $0.2 million on these vested shares, resulting in the issuance of 99,127 net shares to its employees and consultants
Restricted Stock Award Activity [Member]                  
Intrinsic fair value common stock per share               $ 4.73 $ 3.21
Fair value of the RSAs vested               $ 1,400,000 $ 600,000
Minimum | Common Share Issuances [Member]                  
Common stock issuance price               $ 3.00 $ 4.00
Top [Member] | Common Share Issuances [Member]                  
Common stock issuance price               $ 4.00 $ 5.82
2024 Transactions [Member]                  
Equity grant approved by board of directors $ 2,800,000                
Shares of common stock issued 484,269                
Common shares equity grant price per shares $ 5.82                
Description about share compensation               a total of 253,425 RSAs vested. These RSAs vest annually with a three-year straight line vesting period. The Company withheld 100,514 shares to make payments for withholding taxes of $0.4 million on these vested shares, resulting in the issuance of 152,911 net shares to its employees and consultants  
2020 Equity Incentive Plan [Member]                  
Common stock available for future issuance               1,073,914  
Total number of common stock available for future issuance               2,500,000  
Description of Equity incentive plan         the Board of Directors approved an increase of 700,000 shares to the authorized number of shares under the 2020 Plan, increasing the total authorized number of shares from 1,800,000 shares to 2,500,000 shares